- Home
- CANF vs FCUV Comparison
CANF vs FCUV Comparison
Compare CANF & FCUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- FCUV
- Stock Information
- Founded
- CANF 1994
- FCUV 2012
- Country
- CANF Israel
- FCUV United States
- Employees
- CANF N/A
- FCUV N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- FCUV Industrial Machinery/Components
- Sector
- CANF Health Care
- FCUV Industrials
- Exchange
- CANF Nasdaq
- FCUV Nasdaq
- Market Cap
- CANF 14.8M
- FCUV 27.6M
- IPO Year
- CANF N/A
- FCUV N/A
- Fundamental
- Price
- CANF $1.03
- FCUV $4.11
- Analyst Decision
- CANF Strong Buy
- FCUV
- Analyst Count
- CANF 2
- FCUV 0
- Target Price
- CANF $14.00
- FCUV N/A
- AVG Volume (30 Days)
- CANF 145.4K
- FCUV 15.1K
- Earning Date
- CANF 08-29-2025
- FCUV 08-13-2025
- Dividend Yield
- CANF N/A
- FCUV N/A
- EPS Growth
- CANF N/A
- FCUV N/A
- EPS
- CANF N/A
- FCUV N/A
- Revenue
- CANF $674,000.00
- FCUV $408,887.00
- Revenue This Year
- CANF $461.72
- FCUV N/A
- Revenue Next Year
- CANF N/A
- FCUV N/A
- P/E Ratio
- CANF N/A
- FCUV N/A
- Revenue Growth
- CANF N/A
- FCUV 6.49
- 52 Week Low
- CANF $0.98
- FCUV $1.50
- 52 Week High
- CANF $4.69
- FCUV $10.90
- Technical
- Relative Strength Index (RSI)
- CANF 40.76
- FCUV 53.97
- Support Level
- CANF $0.99
- FCUV $3.75
- Resistance Level
- CANF $1.09
- FCUV $4.23
- Average True Range (ATR)
- CANF 0.04
- FCUV 0.24
- MACD
- CANF -0.00
- FCUV 0.06
- Stochastic Oscillator
- CANF 22.22
- FCUV 73.75
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About FCUV Focus Universal Inc.
Focus Universal Inc offers smart devices, IoT products, and patented products and technologies for 5G telecommunications and network security. It is focused on commercializing its universal smart technology and financial reporting software. Its product line includes various digital, analog, and quantum light meters and filtration products, the Ubiquitor universal smart device, SEC Financial Reporting Software, and other smart devices and sensors. The company's reportable segments are Corporate and IoT, which derives maximum revenue, and Perfecular and Lusher. The Corporate and IoT segment includes its LED and IoT installation and management business (under Smart AVX), specializing in LED and display systems, home theaters, lighting control, automation, and integration.